Sangamo Therapeutics (NASDAQ:SGMO) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a report published on Wednesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued research reports about the company. HC Wainwright reiterated a buy rating and issued a $5.00 target price on shares of Sangamo Therapeutics in a research report on Wednesday, May 15th. Royal Bank of Canada reaffirmed a sector perform rating and set a $2.00 price target on shares of Sangamo Therapeutics in a report on Thursday, March 14th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of Hold and a consensus target price of $5.67.

Sangamo Therapeutics Stock Down 5.2 %

SGMO opened at $0.42 on Wednesday. The stock has a market capitalization of $87.86 million, a price-to-earnings ratio of -0.23 and a beta of 1.35. Sangamo Therapeutics has a twelve month low of $0.29 and a twelve month high of $1.67. The company has a 50-day simple moving average of $0.54 and a 200 day simple moving average of $0.62.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05). Sangamo Therapeutics had a negative return on equity of 182.55% and a negative net margin of 1,749.06%. The business had revenue of $0.48 million for the quarter, compared to the consensus estimate of $8.51 million. During the same quarter in the previous year, the company earned $0.12 earnings per share. Sell-side analysts anticipate that Sangamo Therapeutics will post -0.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC raised its stake in shares of Sangamo Therapeutics by 3.7% during the third quarter. Acadian Asset Management LLC now owns 2,927,769 shares of the biopharmaceutical company’s stock valued at $1,753,000 after acquiring an additional 105,789 shares during the last quarter. SG Americas Securities LLC raised its position in Sangamo Therapeutics by 103.9% during the 4th quarter. SG Americas Securities LLC now owns 180,544 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 92,002 shares during the last quarter. Assenagon Asset Management S.A. raised its position in Sangamo Therapeutics by 14.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock worth $561,000 after purchasing an additional 129,811 shares during the last quarter. Mackenzie Financial Corp lifted its holdings in Sangamo Therapeutics by 72.4% during the 4th quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 31,003 shares during the period. Finally, Golden State Equity Partners grew its position in shares of Sangamo Therapeutics by 21.0% in the 4th quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 34,960 shares during the last quarter. Institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.